ACAAI 2024 Insights
ACAAI 2024 Insights: Results From a Phase 2, Randomized, Placebo-Controlled Trial of CRISPR-Based Therapy NTLA-2002 for Hereditary Angioedema
By
ACAAI 2024 Insights
FEATURING
Danny M. Cohn
By
ACAAI 2024 Insights
FEATURING
Danny M. Cohn
Read the full article here: https://www.nejm.org/doi/abs/10.1056/NEJMoa2405734
Comments 0
Login to view comments.
Click here to Login
